Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clarithromycin + fluticasone
- Development stage
- Preclinical
- Lead developer
- Taisho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Inhalation, Intranasal, Topical
01
Overview
This is a combination of clarithromycin, a macrolide antibiotic, and fluticasone, a synthetic glucocorticoid. While not marketed as a fixed combination product, these medications may be prescribed together in certain clinical scenarios. Clarithromycin has antibacterial, anti-inflammatory, and immunomodulatory effects, while fluticasone reduces inflammation. However, there is a significant drug interaction between these medications, as clarithromycin can increase fluticasone blood levels by inhibiting its metabolism.
02
Targets
Bacterial 50S ribosomal subunitGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on clarithromycin + fluticasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clarithromycin + fluticasone.